Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002235 · ClinicalTrials.gov registry record · Phase 2
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00002235: Completed Phase 2 study, sponsored by Merck Sharp & Dohme.
NCT00002235 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002235, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
Interventions
- DRUG Efavirenz
- DRUG Indinavir sulfate
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Phase | Phase 2 |
What the finished NCT00002235 record still lists
NCT00002235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Efavirenz is the first listed.
NCT00002235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002235 about?
NCT00002235 is a clinical study titled "A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors". Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
What is the current status of trial NCT00002235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants.
What interventions are being tested in trial NCT00002235?
The interventions under investigation include: Efavirenz (DRUG), Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002235?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002235's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08